CLINICAL TRIALS PROFILE FOR FLUPHENAZINE HYDROCHLORIDE

All Clinical Trials for Fluphenazine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00014001 ↗	CATIE- Schizophrenia Trial	Completed	National Institute of Mental Health (NIMH)	Phase 4	2000-12-01	The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00161018 ↗	New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia	Completed	University of Maryland	Phase 3	2003-11-01	The purpose of this study is to: 1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency typical antipsychotic in patients who meet the DSM IV criteria for schizophrenia. 2. To evaluate the efficacy and safety of quetiapine (1200mg/day) in patients who have not responded to conventional and newer antipsychotics. 3. To evaluate the effectiveness of quetiapine (300-500mg/day), and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) in the treatment of hostility and aggression in treatment-resistant schizophrenic patients. 4. To evaluate the effectiveness of quetiapine (300-500mg/day) and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) on rates of discharge, quality of life, and independent living skills. 5. To assess prolactin levels and to evaluate any relationship with sexual dysfunction and menstrual irregularities. 6. To evaluate the possible differential impact of treatment conditions on cognitive functioning including measures of attention, motor speed, problem solving, verbal and visual memory, and verbal processing speed. 7. To measure changes in weight and health consequences associated with weight changes.
NCT00161018 ↗	New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia	Completed	University of Maryland, Baltimore	Phase 3	2003-11-01	The purpose of this study is to: 1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency typical antipsychotic in patients who meet the DSM IV criteria for schizophrenia. 2. To evaluate the efficacy and safety of quetiapine (1200mg/day) in patients who have not responded to conventional and newer antipsychotics. 3. To evaluate the effectiveness of quetiapine (300-500mg/day), and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) in the treatment of hostility and aggression in treatment-resistant schizophrenic patients. 4. To evaluate the effectiveness of quetiapine (300-500mg/day) and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) on rates of discharge, quality of life, and independent living skills. 5. To assess prolactin levels and to evaluate any relationship with sexual dysfunction and menstrual irregularities. 6. To evaluate the possible differential impact of treatment conditions on cognitive functioning including measures of attention, motor speed, problem solving, verbal and visual memory, and verbal processing speed. 7. To measure changes in weight and health consequences associated with weight changes.

Clinical Trial Conditions for Fluphenazine Hydrochloride

Condition Name

Condition Name for Fluphenazine Hydrochloride
Intervention	Trials
Schizophrenia	7
Psoriasis	2
Psychotic Disorders	1

Condition MeSH

Condition MeSH for Fluphenazine Hydrochloride
Intervention	Trials
Schizophrenia	7
Disease	3
Psoriasis	2

Clinical Trial Locations for Fluphenazine Hydrochloride

Trials by Country

Trials by Country for Fluphenazine Hydrochloride
Location	Trials
United States	60
India	3
Germany	2
Canada	2

Trials by US State

Trials by US State for Fluphenazine Hydrochloride
Location	Trials
Texas	4
Pennsylvania	4
New York	4
California	3
Massachusetts	3

Clinical Trial Progress for Fluphenazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Fluphenazine Hydrochloride
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Fluphenazine Hydrochloride
Clinical Trial Phase	Trials
Completed	9
Terminated	2
Unknown status	1

Clinical Trial Sponsors for Fluphenazine Hydrochloride

Sponsor Name

Sponsor Name for Fluphenazine Hydrochloride
Sponsor	Trials
Immune Control	4
Tufts Medical Center	2
Canadian Institutes of Health Research (CIHR)	2

Sponsor Type

Sponsor Type for Fluphenazine Hydrochloride
Sponsor	Trials
Other	11
Industry	6
NIH	1

Fluphenazine Hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Fluphenazine Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

What is Fluphenazine Hydrochloride currently in clinical development?

Fluphenazine hydrochloride is an older, off-patent antipsychotic. Public clinical development activity is limited and is not consistently tracked as a modern global “program” across major registries. As a result, there is no reliable, registry-wide snapshot of phase-by-phase trials that can be cited as a consolidated “latest update” for the molecule as a single development asset.

Is there an identifiable pipeline catalyst in major registries?

No consolidated, molecule-level late-stage (Phase 3 or Phase 2/3) development program for fluphenazine hydrochloride can be confirmed from the provided dataset. Publicly visible trial activity, where present, tends to relate to:

• Formulation or bioequivalence studies for generic products
• Regimen or tolerability studies tied to older off-label or guideline-concordant use
• Pharmacokinetic work tied to specific dosage forms

How do those trial patterns affect decision-making?

For investment and R&D planning, fluphenazine hydrochloride behaves like a “mature generics/line-extension” asset rather than a “novel clinical catalyst” asset. The expected value inflection comes from:

• Regulatory and launch execution (generic approvals and market entry)
• Supply chain reliability and distribution coverage
• Local pricing dynamics and payer reimbursement
• Competitor generic intensity in each geography

---

What does the market look like today?

Market category and demand drivers

Fluphenazine hydrochloride is used in schizophrenia and related psychotic disorders. It competes in a market shaped by:

• Long-term maintenance prescribing patterns
• Shifts in clinician preference toward newer antipsychotics
• The continued need for low-cost antipsychotic options in health systems and among patients who tolerate older agents

Competitive landscape

The practical competitive set is dominated by:

• Generic fluphenazine products by route and dose form (oral vs depot formulations where relevant)
• Other low-cost first-generation antipsychotics
• Cheaper-to-treat segments of second-generation antipsychotics where pricing has converged

Pricing and volume behavior

As an older generic, fluphenazine hydrochloride demand typically follows:

• Stable baseline volume
• Pricing pressure as supply increases
• Geographic variability tied to formulary placement, national prescribing guidelines, and tender mechanisms

---

What is a defensible market projection for fluphenazine hydrochloride?

Projection framework for an older generic

For mature off-patent antipsychotics, projections must be built around:

• Expected tender and reimbursement behavior
• Generic supply growth versus competitor exit
• Switching pressure from prescriber trends to newer agents
• Patient continuity on maintenance therapy

Directional outlook

Based on typical behavior of mature off-patent antipsychotics, the near-to-medium-term outlook is:

• Low to mid single-digit volume growth or flat demand in most markets
• Downward or flat pricing driven by generic competition
• Revenue growth lagging volume unless supply constraints reduce price pressure or tender pricing rises

Key projection variables (what moves revenue most)

Variable	Expected direction in mature generic segments	Impact on revenue
Number of competing generics	Often increases	Negative on pricing
Formulary access / tender wins	Cycles by procurement round	Positive if secured, negative if displaced
Route-of-administration adoption (where depot use exists)	Tends to be clinician- and system-dependent	Moderate if preserved
Switch to newer antipsychotics	Gradual pressure in many settings	Negative on long-term volume

---

How do regulatory and patent realities shape the forecast?

Patent landscape

Fluphenazine hydrochloride is not an active, enforceable blockbuster patent platform in most major markets. That removes the core driver of a “patent cliff” scenario and shifts the business risk to:

• Generic entry timing
• Product-specific regulatory posture (bioequivalence, labeling, formulation)
• Manufacturing and quality consistency

Regulatory behavior

For mature generics, the regulatory pathway typically results in:

• Multiple approvals for equivalent products
• Periodic label or manufacturing changes that affect interchangeability

---

What should R&D and business teams prioritize?

If the goal is market expansion

1. Target payer and formulary access in markets where first-generation antipsychotic use remains clinically and economically anchored
2. Build a supply position that can withstand tender and procurement swings (capacity and lead time reliability)

If the goal is differentiation

Differentiate through product reliability rather than “innovation,” given limited clinical upside:

• Manufacturing robustness (fewer stock-outs, consistent potency and release specs)
• Pharmacy-facing packaging and dose-availability alignment
• Labeling clarity where local regulation allows

---

Key Takeaways

• Fluphenazine hydrochloride is best treated as a mature off-patent antipsychotic where value creation is driven by market access, procurement wins, and supply execution rather than new clinical catalysts.
• Publicly observable clinical development activity is limited and is more consistent with generic-related studies than a modern late-stage pipeline that can support a molecule-level investment thesis.
• Market outlook is typically stable to modestly growing in volume with pricing pressure from generic competition; revenue depends on tender and formulary positioning more than on new clinical evidence.

---

FAQs

1) Why is there limited visibility into fluphenazine hydrochloride late-stage trials?

Because it is an older, off-patent molecule where development focus shifts to generic entry and localized studies rather than new Phase 3 programs.

2) What is the biggest driver of revenue growth for fluphenazine hydrochloride?

Formulary placement and tender procurement outcomes in each geography, which govern volume and pricing.

3) Does switching to second-generation antipsychotics materially threaten demand?

It exerts long-term pressure, but mature older antipsychotics often maintain baseline demand where cost and long-term tolerability support continuation.

4) What differentiation strategy works best for mature generics?

Reliability and commercial access: consistent supply, manufacturing performance, and maintaining or expanding reimbursement coverage.

5) Can bioequivalence/formulation studies create meaningful market upside?

Yes at the margin, by enabling launches and preserving interchangeability, but they do not typically reset the molecule’s market trajectory.

---

References

1. FDA Drug Approval Reports: Orange Book search results for fluphenazine hydrochloride (accessed 2026).
2. ClinicalTrials.gov search for “fluphenazine hydrochloride” (accessed 2026).
3. WHO Model Formulary and antipsychotic monographs referencing fluphenazine (accessed 2026).